Rhinocort Switch Makes Three In OTC Intranasal Corticosteroid Market

FDA’s approval of Rhinocort Allergy Spray marketed OTC by McNeil Consumer Healthcareincreases to three the number of competitors in the next great switch category, intranasal corticosteroids.

The Center for Drug Evaluation and Research’s approval of the Johnson & Johnson subsidiary’s supplemental new drug application for the budesonide product (32 mcg per spray) came without an advisory committee opinion, a step the agency required for the first switch in the category, Sanofi’s Nasacort 24 HR (triamcinolone